Education
About Us
Working with TipRanks
Follow Us
Moderna (DE:0QF)
XETRA:0QF
0QF Stock Chart & Stats
€39.46
-€2.54(-5.63%)
At close: 4:00 PM EST
€39.46
-€2.54(-5.63%)
Day’s Range― - ―
52-Week Range€19.37 - €46.96
Previous CloseN/A
Volume96.78K
Average Volume (3M)29.20K
Market Cap
€15.49B
Enterprise Value€17.53B
Total Cash (Recent Filing)€5.80B
Total Debt (Recent Filing)€1.92B
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Apr 30, 2026EPS Estimate
-1.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding390,733,640
10 Day Avg. Volume29,326
30 Day Avg. Volume29,203
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€30.17Price Target Upside-23.55% Downside
Rating ConsensusHold
Number of Analyst Covering19
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial Position And Cost DisciplineSignificant operating expense reductions, improved working capital, and access to committed financing strengthen the company's cash runway and flexibility to fund late-stage oncology and rare disease programs.
International Commercial ExpansionClearer international agreements for the COVID vaccine and opportunities as competitor exclusivities lapse support higher revenue expectations outside the United States and diversify geographic risk.
Regulatory ProgressFDA acceptance of the flu vaccine filing and a defined regulatory review pathway increases the prospect of U.S. authorization and access to the older adult influenza market.
Bears Say
Regulatory Obligations And Post-approval Study BurdenA likely requirement to run a large post‑marketing vaccine efficacy study in older adults would increase development costs, delay full market access, and add uncertainty to the commercial profile of the flu program.
Trial Design And Comparator UncertaintyEarlier regulatory concerns about trial design and unresolved comparator selection undermine confidence in the approval pathway for the influenza program and raise the risk of further regulatory setbacks.
U.S. Market Demand And Valuation RiskPersistent U.S. policy headwinds, weak vaccination uptake, and strong competition, combined with a prior stock rally that may reflect anticipated milestones, could limit upside from future commercial developments.
Moderna News
0QF FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was €19.37 and its highest was €46.96 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is €15.49B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Apr 30, 2026 which is in 68 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Feb 13, 2026. The company reported -€1.795 earnings per share for the quarter, beating the consensus estimate of -€2.164 by €0.369.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -1.73.
How many shares outstanding does Moderna have?
Moderna has 390,733,640 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -€1.795 in its last earnings report, beating expectations of -€2.164. Following the earnings report the stock price went up 14.108%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in DE:0QF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€30.17 (-23.55% Downside)
€30.17 (-23.55% Downside)
Blogger Sentiment
Bullish
DE:0QF Sentiment 84%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $703.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 52%
Bearish news 48%
Bearish news 48%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.44%
12-Months-Change
Fundamentals
Return on Equity
-28.87%
Trailing 12-Months
Asset Growth
-12.76%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
0QF Company Deck
0QF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights meaningful operational and commercial progress — notably strong MNEXT Spike launch, substantial cost reductions (operating expenses down 30%, cost of sales down 41%, R&D down 31%), improved losses and a healthy cash balance — alongside multiple clinical and commercial catalysts (fully enrolled late‑stage trials, strategic partnerships, international filings). Major risks include the FDA refusal to file for the flu vaccine, continued net losses and cash runoff toward 2026, and reliance on event‑driven readouts and international approvals for growth. Overall, the company demonstrated strong execution and cost discipline but faces material regulatory and timing risks that temper near‑term visibility.View all DE:0QF earnings summaries0QF Revenue Breakdown
55.16% U.S.
18.48% Europe
26.36% Rest of World
0QF Stock 12 Month Forecast
Average Price Target
€30.17
▼(-23.55% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―
Options Prices
Currently, No data available
---